Answers are grounded in this paper and cite their sources.
Invasive fungal disease (IFD) poses a significant threat to the lives of patients with hematological malignancies. However, it remains unclear whether monotherapy or combination antifungal treatment is more effective for these patients. To address this question, our study aimed to evaluate and compare the efficacy and safety of antifungal combination therapies versus monotherapies in the treatment of IFD in patients with hematological malignancies. This study compared the response rates to treatment, breakthrough IFD, IFD-associated deaths and overall mortality within 90 days, and adverse events in patients with hematological malignancies who were clinically diagnosed with IFD or suspected IFD and who had received caspofungin (CAS), voriconazole (VRC), or liposomal amphotericin B (L-AmB) or their combination. CAS, VRC, and L-AmB monotherapies were administered to 150, 148, and 50 patients, respectively; 65, 54, and 26 patients received CAS + VRC, CAS + L-AmB, and VRC + L-AmB combination therapies, respectively. The response rates did not differ significantly among the CAS, VRC, and CAS + VRC combination groups (P > 0.05), and this combination was not associated with significantly different outcomes in this cohort. The response rates were higher for CAS and VRC than for L-AmB monotherapy (P < 0.05). All adverse events were more common in patients receiving L-AmB monotherapy or combination therapy than in those receiving CAS monotherapy (P < 0.05). The overall adverse event rate was higher with L-AmB monotherapy than with VRC monotherapy (P < 0.05). In this cohort, patients who received CAS + VRC, CAS + L-AmB, or VRC + L-AmB were not associated with significantly different outcomes compared with those receiving CAS or VRC monotherapy; however, given the retrospective, single-centre design and the small subgroup sizes, these findings are exploratory and cannot establish equivalence or superiority between monotherapy and combination therapy. The use of L-AmB seems to be associated with a higher incidence of adverse reactions. • The response rates did not differ among the caspofungin, voriconazole, and their combination groups. • Caspofungin and voriconazole are associated with statistically higher response rates than liposomal amphotericin B. • Voriconazole is associated with more hepatotoxicity. • Liposomal amphotericin B is associated with more hypokalemia and nephrotoxicity.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: